

Table of Contents

Introduction	1
Section 1: GCP Regulations, Standards, and Guidelines for Clinical Research	5
Section 2: Investigators/Sites	31
Section 3: Study Sponsors and Investigator Site Monitoring.....	73
Section 4: Informed Consent	95
Section 5: Source Data/Documentation.....	119
Section 6: Clinical Trial Protocols/Protocol Changes/Protocol Violations	155
Section 7: Institutional Review Boards and Ethics Committees	171
Section 8: Drug/Study Safety and Safety Reporting	211
Section 9: Quality Assurance & Auditing	241
Section 10: Regulatory Inspections	247
Section 11: Clinical Data Management.....	263
Section 12: Computerized Systems, Electronic Records, and e-Data Integrity	277
Section 13: Patient Recruitment and Clinical Trial Diversity	293
Section 14: Conflicts of Interest/Financial Disclosure	303
Section 15: The HIPAA Privacy Rule and FDA-Regulated Clinical Trials	335
Section 16: Investigational Medicinal Product Management.....	357
Section 17: Fraud, Negligence, and Regulatory Non-Compliance	377
Section 18: The Trial Master File.....	395
Section 19: Risk Based Quality Management/Quality by Design.....	407
Section 20: Impact of World Events on Clinical Trial Management.....	425
Section 21: Decentralized Clinical Trials	433
Section 22: European Privacy and Data Protection/GDPR	441
Appendix: GCP Compliance Statistics and Trends	449
Index.....	457

Tables & Figures

US Food and Drug Administration (FDA) Inspection Metrics (2022)	449
Number of BIMO Inspection Classifications by Center FY2022* (* Domestic and Foreign).....	449
Common Clinical Investigator Inspectional Observations	449
Common Institutional Review Board Inspectional Observations.....	449
Common Sponsor/Monitor/CRO Inspectional Observations	450
Common Sponsor-Investigator Inspectional Observations.....	450
Medicines & Healthcare Products Regulatory Agency (MHRA) GCP Inspection Metrics (2020).....	451
European Medicines Agency (EMA) GCP Inspection Metrics (2022).....	455